Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $10.80 Average PT from Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $10.80.

SANA has been the subject of several recent analyst reports. TD Cowen raised shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research report on Wednesday, January 8th. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They issued a "buy" rating and a $7.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $11.00 price objective on shares of Sana Biotechnology in a report on Tuesday, March 18th. Finally, Citizens Jmp upgraded Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research note on Tuesday, March 18th.

Hedge Funds Weigh In On Sana Biotechnology

A number of hedge funds have recently added to or reduced their stakes in SANA. China Universal Asset Management Co. Ltd. grew its stake in shares of Sana Biotechnology by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,341 shares of the company's stock worth $77,000 after acquiring an additional 4,554 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Sana Biotechnology by 17.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company's stock worth $146,000 after purchasing an additional 5,338 shares during the last quarter. Teacher Retirement System of Texas grew its position in Sana Biotechnology by 20.3% in the 4th quarter. Teacher Retirement System of Texas now owns 36,797 shares of the company's stock worth $60,000 after purchasing an additional 6,209 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Sana Biotechnology by 2.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company's stock valued at $457,000 after buying an additional 6,613 shares during the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Sana Biotechnology by 51.0% during the 4th quarter. Blue Trust Inc. now owns 19,823 shares of the company's stock worth $32,000 after buying an additional 6,694 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock traded up $0.23 during midday trading on Tuesday, reaching $1.76. The company had a trading volume of 5,508,724 shares, compared to its average volume of 3,288,495. The firm has a market cap of $396.04 million, a PE ratio of -1.26 and a beta of 1.78. The stock has a fifty day moving average price of $2.38 and a 200 day moving average price of $2.81. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $10.50.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. As a group, sell-side analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.